Taylor Wessing Prague has advised Germany's Biotest group and its subsidiary Plasma Service Europe on their acquisition of Cara Plasma s.r.o., which operates plasma centers in the Czech Republic. Terms and conditions of the transaction were not disclosed.
According to Taylor Wessing Prague, "Biotest is a specialist in innovative haematology, clinical immunology and intensive care medicine. Biotest develops, manufactures and markets plasma proteins and biotherapeutic drugs. The value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Biotest manufactures immunoglobulins, clotting factors and albumins which derive from human blood plasma. Biotest also develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest currently employs more than 2,500 people worldwide."
The firm reports that Cara Plasma, which was founded in 2013 by a Czech family, "established a state-of-the-art blood collection center in Prague which is one of Europe´s top 10. The center was opened in September 2013."
The Taylor Wessing team was led by Prague Partner Thilo Hoffmann, supported by Associate Denisa Rajdova.
Taylor Wessing did not identify counsel for the sellers.